T Cell News and Research

Latest T Cell News and Research

Researchers have identified a protein called HIF-2a, which is important in retina formation

Hoping to prevent blindness in premature babies, UT Southwestern Medical Center researchers have identified a protein that responds to oxygen levels in cells and tissues and also affects the developing eye.

22 Feb 2005

Scientists have replicated hepatitis C virus (HCV) in the laboratory

For the first time, scientists have replicated hepatitis C virus (HCV) in the laboratory. The ability to replicate HCV in cell culture will allow researchers to better study the life cycle and biology of this virus and to test potential antiviral compounds, which may lead to new therapies for the liver disease that results from infection with HCV.

22 Feb 2005

State-of-the-art computer technology to tackle deadly diseases such as influenza

Researchers at the University of Bath have won a £261,000 grant to use the latest software to produce a blueprint of a designer drug that could stop influenza and some other diseases from replicating in humans.

22 Feb 2005

Benitec announces AIDS collaboration

Benitec today announced a collaboration with City of Hope (based in Duarte California) to develop a novel T-cell based therapy for AIDS patients.

22 Feb 2005

Differing forms of taste genes mean that we all live in our own unique taste world

A study published in the February 22 issue of Current Biology confirms the influential role of genetics in determining the wide range of human sensitivity to taste, ultimately impacting how we each perceive the world in a slightly different way.

22 Feb 2005

Secreted signaling protein called Wnt10b secret to new drugs for preventing or treating osteoporosis

Leaping tall buildings in a single bound may be out of the question, but the genetically engineered "supermice" in Ormond MacDougald's laboratory at the University of Michigan Medical School are definitely stronger than average.

22 Feb 2005

Why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa)

Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) have found an explanation for why some lung cancers stop responding to the drugs erlotinib (Tarceva) and gefitinib (Iressa).

22 Feb 2005

Cell phones useful and feasible for visualizing leg wounds

Use of cell phones to send images via e-mail to consulting physicians at remote locations appears to be a feasible approach for visualization of chronic leg ulcerations, according to an article in the current issue of Archives of Dermatology.

21 Feb 2005

New compound, AMN107, 20 times more potent than Gleevec for chronic myelogenous leukemia treatment

A laboratory study led by researchers at Dana-Farber Cancer Institute has shown that a potent and highly selective therapy for chronic myelogenous leukemia (CML) may ultimately be more effective than Gleevec®, the current standard of care.

21 Feb 2005

Crystallized molecular machine reveals possible new paths for treating diseases

The crystallized form of a molecular machine that can cut and paste genetic material is revealing possible new paths for treating diseases such as some forms of cancer and opportunistic infections that plague HIV patients.

21 Feb 2005

New findings on the regulation of cellular growth

A greatly increased synthesis of new proteins is one of the first and most important events that occur in both normal and tumour cells upon growth stimulation.

21 Feb 2005

Biologic therapies are changing the way dermatologists treat psoriasis

Recently approved and investigational biologic therapies are changing the way dermatologists treat psoriasis, a chronic disease that physically and emotionally challenges 4.5 million Americans. As more research is conducted into the effectiveness of these biologics, they are showing great promise for improving the health and well-being of patients with psoriasis.

20 Feb 2005

New bone marrow model could help people with sickle cell disease

A new model showing how sickle cell blood cells operate within bone marrow is presented at a conference in Austria today. Researchers at Imperial College London, who developed the model, hope that it will eventually be used by clinicians to advance more effective treatments for sickle cell disease.

20 Feb 2005

Green tea protects livers

A new study investigating the effects of the major flavonoid component of green tea on hepatic steatosis (fatty liver) found that it significantly protected livers that suffered ischemia/reperfusion (I/R) injury in mice. I/R injury, which is caused by decreased blood flow, can lead to complications after liver transplantation.

20 Feb 2005

Vaccine that boosts the immune response could improve the effect of conventional treatment for patients with chronic myeloid leukaemia

CML is caused by the breakage and swapping of chromosomes 9 and 22, which results in a shortened chromosome called the Philadelphia chromosome. Cells with the abnormal chromosome make a protein that encourages aberrant growth and division. Patients with CML can be treated with a drug called imatinib or interferon alfa.

20 Feb 2005

Air pollution thickens the blood and boosts inflammation

Air pollution, and especially particulate matter, thickens the blood and boosts inflammation, finds experimental research in Occupational and Environmental Medicine.

20 Feb 2005

Studies reveal methods viruses use to sidestep immune system

A series of studies by researchers at UT Southwestern Medical Center sheds light on the mechanisms used by viruses to thwart a host's immune defenses and may aid in the development of more effective drugs to fight hepatitis C and West Nile viruses, as well as the flu and the common cold.

17 Feb 2005

Massachusetts support of stem cell research

The Massachusetts Medical Society, the statewide association of physicians with some 18,000 members, has offered testimony before the Joint Committee on Economic Development and Emerging Technologies in support of Senate Bill 25, An Act Promoting Stem Cell Research.

17 Feb 2005

Nonsurgical microspheres an option for liver cancer patients

A study in February’s Journal of Vascular and Interventional Radiology found that patients undergoing liver cancer treatment with Theraspheres?, radioactive microspheres containing Yittrium-90, can tolerate a 150 Gy single dose or 268 Gy repeated dose without risk of radiation-induced liver disease.

17 Feb 2005

GenoMed files gene patents

GenoMed has filed a patent application on two additional genes linked to common cancers. These genes are the third and fourth identified as a result of GenoMed's research in 2005 to date. They have the potential to improve the outcomes for those individuals afflicted with these cancers.

16 Feb 2005